The purpose of this work was to develop a method to automatically monitor response to neoadjuvant treatment in breast cancer using longitudinally registered multi-b diffusion MRI acquisitions. The two slowest diffusion signal contributions from a three-component model were used to generate cancer probability maps (C1C2 classifier) that estimated tumor volume at each timepoint. Our results demonstrated that changes in C1C2 classifier agreed with standard dynamic-contrast-enhanced MRI criteria (RECIST) in 23 out of 24 cases. In 35% of treatment responders, the C1C2 classifier captured response at an earlier timepoint than RECIST.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords